GlassScriptPhysician profile
Fahd A Zarrouf
NPI 1396867461
$4,534.15
in general payments reported to CMS, 2019-2025
20 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $141 · 2021: $414 · 2022: $143 · 2023: $1,461 · 2024: $798 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Travel and Lodging: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.12 |
| Travel and Lodging | $1,199.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,526.12 | 2021-2025 | Inspire |
| Axsome Therapeutics, INC. | $537.08 | 2024-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $527.86 | 2019-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $295.31 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $206.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $189.57 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Avadel Cns Pharmaceuticals, LLC | $177.96 | 2025 | Lumryz |
| Lilly USA, LLC | $137.09 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $131.09 | 2019-2025 | |
| Eisai INC. | $125.00 | 2019 | |
| Bioxcel Therapeutics, INC. | $125.00 | 2023 | Igalmi |
| Astrazeneca Pharmaceuticals LP | $123.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $121.19 | 2021-2025 | Fanapt |
| Noctrix Health, INC. | $90.08 | 2024 | Nidra |
| Neuronetics, INC. | $66.69 | 2022-2023 | Neurostar Tms Therapy System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $55.61 | 2023 | Fisher & Paykel Healthcare |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| Philips North America LLC | $25.46 | 2022 | |
| Harmony Biosciences LLC | $25.15 | 2022 | |
| Neurocrine Biosciences, INC. | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahd Zarrouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.